896139-85-8

Usage

Uses

Used in Pharmaceutical Industry:
Imidazo[1,2-a]pyridin-7-ol is used as an intermediate for the synthesis of heterocyclic compounds that function as tyrosine kinase inhibitors and anticancer agents. Its role in the development of these compounds is crucial for creating effective treatments against various types of cancer.
Imidazo[1,2-a]pyridin-7-ol's chemical properties and structural features make it a valuable building block in the creation of targeted therapies that can selectively inhibit the activity of specific tyrosine kinases, which are often implicated in the progression of cancer cells. By serving as an intermediate in the synthesis of these therapeutic agents, Imidazo[1,2-a]pyridin-7-ol contributes to the advancement of cancer treatment options and the improvement of patient outcomes.

InChI:InChI=1/C7H6N2O/c10-6-1-3-9-4-2-8-7(9)5-6/h1-5,10H

Upstream product

• 107-20-0 2-chloroethanal 
• 33631-05-9 2-amino-4-hydroxypyridine 
• 4532-25-6 7-chloroimidazo-[1,2-a]pyridine 
• 808744-34-5 7-bromoimidazo[1,2-a]pyridine 

Downstream Products

• 1251863-67-8 C₂₆H₃₁F₃N₄O₅ 
• 1251863-09-8 1-{3-[7-(2-Hydroxy-ethoxy)-imidazo[1,2-a]pyridin-3-yl]-5-isopropoxy-phenyl}-3-(2,2,2-trifluoro-ethyl)-urea 

Relevant academic research and scientific papers

ErbB RECEPTOR INHIBITORS AS ANTI-TUMOR AGENTS

Provided herein are novel compounds as inhibitors of type I receptor tyrosine kinases, the pharmaceutical compositions comprising one or more of the compounds and salts thereof as an active ingredient, and the use of the compounds and salts thereof in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals and especially in humans.

NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND APPLICATION

A nitrogenous heterocyclic compound, a preparation method, an intermediate, a composition, and an application. The present invention provides a nitrogenous heterocyclic compound as represented by formula I, pharmaceutically acceptable salts thereof, enantiomers thereof, diastereoisomers thereof, tautomers thereof, solvates thereof, metabolites thereof, or prodrugs thereof. The compound has high inhibitory activity against ErbB2 tyrosine kinase, has good inhibitory activity against human breast cancer cells BT-474, human gastric cancer cells NCI-N87 and the like with high expression of ErbB2, and in addition has relatively weak inhibitory activity against EGFR kinase, that is, the compound is an EGFR/ErbB2 double target inhibitor that attenuates EGFR kinase inhibitory activity or a small-molecule inhibitor having selectivity for an ErbB2 target. (I)

Imidazo[1,2-a]pyridine compound, and preparation method and applications thereof

The invention discloses an imidazo[1,2-a]pyridine compound, and a preparation method and applications thereof. The imidazo[1,2-a]pyridine compound can inhibit the activity of NEK2 kinases as an NEK2 micro-molecular inhibitor with a novel structure. The in

Copper-Catalyzed Hydroxylation of (Hetero)aryl Halides under Mild Conditions

The combination of Cu(acac)2 and N,N′-bis(4-hydroxyl-2,6-dimethylphenyl)oxalamide (BHMPO) provides a powerful catalytic system for hydroxylation of (hetero)aryl halides. A wide range of (hetero)aryl chlorides bearing either electron-donating or -withdrawing groups proceeded well at 130 °C, delivering the corresponding phenols and hydroxylated heteroarenes in good to excellent yields. When more reactive (hetero)aryl bromides and iodides were employed, the hydroxylation reactions completed at relatively low temperatures (80 and 60 °C, respectively) at low catalytic loadings (0.5 mol % Cu).